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Prescribe to Prevent: Overdose Prevention and Naloxone
Rescue Kits for Prescribers and Pharmacists
Jamie K. Lim, BSc, Jeffrey P. Bratberg, PharmD, Corey S. Davis, JD, MSPH, Traci C. Green, PhD, MSc,
and Alexander Y. Walley, MD, MSc
InMarch of 2015, the United States Department of Health and Human
Services identified 3 priority areas to reduce opioid use disorders and
overdose,which are as follows: opioid-prescribingpractices; expanded
use anddistribution of naloxone; and expansion ofmedication-assisted
treatment. In this narrative review of overdose prevention and the role
of prescribers and pharmacists in distributing naloxone, we address
these priority areas and present a clinical scenario within the review
involving a pharmacist, a patient with chronic pain and anxiety, and a
primary care physician. We also discuss current laws related to
naloxone prescribing and dispensing. This review was adapted from
the Prescribe to Prevent online continuing medical education module
created for prescribers and pharmacists (http://www.opioidprescri-
bing.com/naloxone_module_1-landing).
Key Words: pain, prescription drug abuse, prevention, public
health, substance abuse
(J Addict Med 2016;10: 300–308)
Clinical scenario: Upon filling a prescription for oxyco-
done, a pharmacist reviews the patient’s other medications:
‘‘In the Prescription Monitoring Program, I see that you’re
also being prescribed clonazepam by another physician. I
wanted to make sure that you understand that combining
pain medications, like oxycodone, and anxiety medi-
cations, like clonazepam, can increase your risk of drowsi-
ness, sedation, and even overdose.’’ The patient replies that
she has been taking these medications for a long time and is
not concerned. ‘‘I’m glad to hear that you’re aware of the
risks,’’ the pharmacist says, ‘‘With your permission, I’m
going to contact your prescribers, so we can monitor your
risk and keep you safe.’’
EPIDEMIOLOGY
Drug overdose, driven largely by use of prescription
opioids and heroin, is now the leading cause of accidental
injury death in the United States, surpassing those caused by
motor vehicle crashes (U.S. Food and Drug Administration,
2014; U.S. Centers for Disease Control and Prevention, 2015a,
2015b). From 2005 to 2013, annual opioid-related overdose
deaths almost doubled, from 12,937 to 24,492 (Jones et al.,
2013;Wheeler et al., 2015). The economic costs to society have
been projected to surpass $20 billion every year (Inocencio
et al., 2013). This overdose crisis has been linked to the
availability and potency of prescribed opioids (Okie, 2010;
Modarai et al., 2013; Chen et al., 2014; Dart et al., 2015).
Whereas 71% of those who are at risk to misuse pain relievers
report obtaining the medications from family and friends, 79%
of those family and friends report being prescribed those
medicines by their doctor (Substance Abuse andMental Health
Services Administration, 2011). Both qualitative and epide-
miologic studies have also demonstrated that heroin addiction
is often preceded by prescription opioid misuse (Jones, 2013;
Dasgupta et al., 2014; Mars et al., 2014; LaRochelle et al.,
2015). Furthermore, fentanyl-related overdose fatalities have
increased, involving fentanyl manufactured and distributed
illicitly as part of the street drug market (U.S. Centers for
Disease Control and Prevention, 2015c).
How Does an Opioid Overdose Occur?
Opioid receptors are found throughout the nervous
system, including the sections of the brainstem that control
breathing. Stimulation of the receptors by opioids can cause
euphoria, pain relief, sedation, and decreased respiration.
High doses of opioids cause reduced sensitivity to oxygen
and carbon dioxide levels, reducing respiratory drive and
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allowing tidal volume and respiratory rate to decrease. The
resulting hypoxia can cause a loss of consciousness, and
eventually, death. Signs of an overdose include decreases
in respiratory rate, abnormal breathing sounds (snoring, gur-
gling, choking, etc.), decreased consciousness, miosis, and a
blue/gray tinge of the skin, especially the lips and nail beds
(White and Irvine, 1999).
PREVENTION
What are Common Risks for Opioid Overdose?
Medical providers and pharmacists should understand,
explain to patients, and take actions to reduceoverdose risk. The
following should be considered when assessing a patient’s risk.
First,previous nonfatal overdose is associatedwith future
overdose (Kinner et al., 2012). Second, higher opioid doses,
such as daily doses higher than 50 morphine milli-equivalents
(Dunn et al., 2010), and changes in dose or formulations
increase overdose risk; people who use heroin are thus fre-
quently at risk due to unpredictable changes in substance purity
from, for example, adulteration with fentanyl (Rudd et al.,
2015). Third, polypharmacy and mixing substances contribute
to overdose risk, as opioid overdoses commonly involve other
substances (Jones et al., 2013, 2014). Psychoactivemedications
of particular concern include barbiturates, stimulants, and
benzodiazepines (Jann et al., 2014; Zedler et al., 2014; Jones
and McAninch, 2015). Other medications that can have syn-
ergistically central nervous system depressive effects include
clonidine (Beuger et al., 1998), promethazine (Shapiro et al.,
2013; Lynch et al., 2015), and gabapentin (Smith et al., 2015).
Fourth, socially isolated individuals who use prescription
opioids or heroin alone have little chance of being rescued.
Isolation is also associated with depression, which is itself
associated with overdose (Cacioppo et al., 2006; Madadi et al.,
2013). Fifth, chronic medical illnesses involving organs, such
as the lung, liver, kidney, and brain, primarily responsible for
metabolizing substances and respiration, can compromise the
body’s ability to handle opioids (Zedler et al., 2014). Sixth,
periods of abstinence, such as periods of incarceration, hospi-
talization, and medical detoxification, cause reduced opioid
tolerance and thus increased overdose risk. Accordingly, pro-
viders should educate andmonitor patients restarting opioids or
at risk of relapse (Wolff, 2002; Strang et al., 2003;Moller et al.,
2010).
Assessing a Patient’s Overdose Risk
Prescribers should assess overdose risk as part of a
patient’s history by the following means: reviewing medi-
cations and checking the Prescription Monitoring Program
(PMP); reviewing medical and social history for above-men-
tioned risk factors; obtaining a focused substance use history;
and obtaining an overdose history. The overdose history should
determine if the patient has personally experienced an overdose
(‘‘Have you ever overdosed? What strategies do you use to
prevent yourself from overdosing?’’), witnessed an overdose
(‘‘Have you witnessed an overdose?’’), or received training to
prevent, recognize, and/or respond to one (‘‘How would you
respond to an overdose?’’). Understanding the patient’s experi-
ence and knowledge should guide the education provided.
Pharmacists should review medications, optimize medi-
cation safety, and provide patient education. This includes
checking the PMP for psychoactive or sedating medications,
addressing potential drug–drug interactions, ensuring that
prescribers are aware of the patient’s prescriptions, confirm-
ing understanding of the risks of opioids, providing overdose
education, and filling naloxone prescriptions, or, when
permitted, directly providing naloxone to the patient.
The pharmacist calls the primary care doctor: ‘‘I saw your
patient has prescriptions for both oxycodone and clonaze-
pam and informed her of the risks of combining these
medications’’ The doctor replies, ‘‘I was not aware of
the clonazepam prescription. Who is the prescriber?’’
The pharmacist offers the other prescriber’s name, which
the doctor recognizes. ‘‘That makes sense. He’s a psychia-
trist that I refer my patients to. I’ll discuss the risks with the
patient at our appointment coming up.’’
Strategies to Address Overdose
There are several existing strategies that address the
Department of Health and Humans Services’ priority areas of
improving opioid-prescribing safety and access to medi-
cation-assisted treatment (U.S. Department of Health and
Human Services, 2015). Safe opioid-prescribing education
has been supported by the Federal Drug Administration
(FDA) and is mandated in some states like Massachusetts
for prescribers to be relicensed (U.S. Food and Drug Admin-
istration, 2013). PMPs allow for prescribers and pharmacists
to monitor what controlled substances a patient is filling at the
pharmacy (Paulozzi et al., 2011; Davis et al., 2014a). Evi-
dence of their effectiveness as overdose prevention tools is
still mixed (Li et al., 2014; Green et al., 2015a). Prescription
drug disposal in many communities occurs at kiosks, often
hosted at local police stations and other locations, with
support fromDrug Enforcement Administration (DEA) which
holds nationwide ‘‘take-back’’ events (Gray and Hagemeier,
2012; U.S. Drug Enforcement Administration, 2015). The
DEA now also permits manufacturers, distributors, treatment
programs, pharmacies, and healthcare facilities to become
authorized collectors of prescription medications (U.S. Drug
Enforcement Administration, 2014). Finally, medication for
opioid use disorders, specifically methadone, buprenorphine,
and naltrexone, is supported by evidence for increased absti-
nence and decreased opioid use (Schwartz et al., 2006;
Mattick et al., 2009; Krupitsky et al., 2011; Mattick et al.,
2014). Methadone and buprenorphine treatment is also associ-
ated with decreased criminal activity (Bell et al., 1997; Dolan
et al., 2005; Lobmann and Verthein, 2009; Bukten et al., 2012;
Soyka et al., 2012), improved birth outcomes (Johnson et al.,
2001; Fajemirokun-Odudeyi et al., 2006; Meyer et al., 2012),
and less overdose (Langendam et al., 2001; Clausen et al.,
2009; Schwartz et al., 2013).
‘‘Your pharmacist contacted me about the risks of taking
both clonazepam and oxycodone,’’ the doctor informs
the patient at their appointment. The patient does not
understand the concern. The doctor explains that these
medications have interactions that increase the chance of
drowsiness and overdose, especially if she uses substances
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like alcohol or other drugs. ‘‘Do you ever feel drowsy or
sedated from your medications?’’ The patient acknowl-
edges one event when she took an extra oxycodone and
clonazepam, after which her husband had trouble waking
her up. The patient says that she now never takes anything
more than what she is prescribed, and knows to call the
doctor if she is struggling with pain, and her psychiatrist if
she is struggling with her anxiety.
When the doctor asks how she stores her medication, she
reports that she has started hiding pills from her son, ‘‘He
got his wisdom teeth out and was given pain medication,
and then he sprained his ankle and was given even more.
I’m worried he has a drug problem and has switched over
to heroin.’’ According to the patient, on previous occasions
after leaving treatment, he immediately relapsed, and she is
now worried about him overdosing. The doctor reiterates
the risk of overdose following a period of abstinence, and
asks if she has a plan if her son should overdose. The
patient says that she knows to call an ambulance and start
rescue breathing, ‘‘But what else can I do?’’
RESPONSE
What are Naloxone Rescue Kits?
Naloxone is an opioid antagonist that displaces opioids
from brain receptors and restores breathing and conscious-
ness. Naloxone is a prescription medication, but not a con-
trolled substance. It usually takes 2 to 5 minutes to take effect
and wears off after 30 to 90 minutes, so patients on long-
acting opioids like methadone and extended-release oxyco-
done may have recurrent reduced respirations and overdose
(Chamberlain and Klein, 1994). Overdose responders should
be encouraged to stay with the person overdosing after
administration of naloxone. In cases of polysubstance or high
potency fentanyl-related overdose, standard doses of nalox-
one may be insufficient, and thus rescue breathing and help
from the emergency medical providers may be necessary to
reverse the overdose. Administering naloxone may precipitate
withdrawal symptoms in the victim.
There are multiple reasons to equip people in the com-
munity with a naloxone rescue kit. First, most opioid users do
not use alone, and sohave people around them that can intervene
should an overdose occur (Baca and Grant, 2007; Powis et al.,
1999). Second, risk factors for overdose have been identified, as
discussed above. Third, the extent of hypoxic brain injury is
time-dependent, so the sooner hypoxia is reversed, the better
(Michiels, 2004). Fourth, bystanders can be trained to recognize
and respond effectively to overdoses with naloxone (Green
et al., 2008; Clark et al., 2014). Finally, fear of being arrested
sometimes discourages bystanders from calling for medical
assistance, and thus makes naloxone an important tool for
people hesitant to call for help (Davis et al., 2013).
Naloxone rescue kits have been endorsed by numerous
organizations, including the American Medical Association
(American Medical Association, 2015), American Society of
Addiction Medicine (American Society of Addiction Medi-
cine, 2014), American Pharmacists Association (American
Pharmacists Association, 2014), Substance Abuse and
Mental Health Services Administration (Substance Abuse
and Mental Health Services Administration, 2014), World
Health Organization (World Health Organization, 2014), and
United Nations Office on Drugs and Crime (United Nations
Office on Drugs and Crime, 2014). In 2015, the American
Heart Association published guidelines on opioid overdose
response with naloxone in an update to their guidelines for
cardiopulmonary resuscitation and emergency cardiovascular
care (Lavonas et al., 2015, Figure 1).
What Evidence Exists to Support Overdose
Prevention Education and Naloxone Rescue
Kits?
Overdose education and naloxone distribution programs
have existed since the late 1990s as community-based initiat-
ives based out of harm-reduction programs (Maxwell et al.,
2006; Sporer and Kral, 2007; Wheeler et al., 2012). Between
1996 and 2014, community organizations reported providing
naloxone rescue kits to 152,283 laypersons and received
reports of 26,463 overdose reversals (Wheeler et al., 2015).
Studies have shown feasibility of naloxone rescue kits
in several different populations (Piper et al., 2008; Doe-
Simkins et al., 2009; Enteen et al., 2010; Bennett et al.,
2011; Walley et al., 2013a). Nonmedical bystanders can be
effectively trained to respond to overdose (Green et al., 2008;
Tobin et al., 2009; Wagner et al., 2010). Some have expressed
concern that naloxone availability would result in increased
opioid use, but this has not been observed. Drug treatment
rates have either stayed constant or increased (Seal et al.,
2005; Doe-Simkins et al., 2014). In several communities in
which programs were implemented, overdose rates have
decreased (Maxwell et al., 2006). In Massachusetts, where
there was heterogeneous rollout of overdose prevention pro-
grams, communities with naloxone distributed to 1 to 100
people per 100,000 population saw opioid overdose death
rates decrease by 27%, whereas in communities with nalox-
one distributed to over 100 people per 100,000 population,
opioid overdose death rates declined by 46% (Walley et al.,
2013b). In a 2013 study, a best-case scenario determined a
cost of $438 per quality-adjusted life year (QALY) gained,
whereas in the worst-case scenario, the cost was $14,000 per
QALY gained (Coffin and Sullivan, 2013).
Talking with Patients About Overdose Prevention and
Response with Naloxone
Messages that providers can convey to patients:
 Only take opioids prescribed to you and as directed;
 If you are worried about your use of opioids, you can talk to me about it;
 If you are not taking opioids safely, I can help you find treatment;
 Make sure your prescribers and pharmacist are aware of all of your
medications;
 Don’t mix opioids with other drugs or alcohol;
 Store medication in a safe and secure place, and dispose of unused
medication;
 Abstinence can change tolerance, so if you stop taking opioids, a lower
dose may be needed upon restart;
 Teach friends and family how to respond to an overdose, including how
to use naloxone and where you store it;
 Know how to recognize and respond to an overdose when you
witness one.
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The doctor provides guidance for the patient and her son.
‘‘First, I’d like to monitor your medications more closely.
I’m going to call your psychiatrist to discuss whether we
should adjust your medications to something safer. I also
recommend that you use a lock box, which you can get at
the pharmacy, to secure your medications.’’ The doctor
then devises a plan for her son. ‘‘Ask him to consider a
treatment program that includes a medication for opioid
addiction, like methadone or buprenorphine—here is a
card to contact the treatment hotline. Lastly, for both
you and your son, I’m going to prescribe a naloxone rescue
kit. The kit includes a medication called naloxone, and
comes with instructions on how to recognize and respond
to an overdose.’’
Naloxone Rescue Kits at the Pharmacy:
Prescribing, Stocking, Filling, and Billing
Prescribing naloxone rescue kits should be a collabo-
rative effort between prescribers and pharmacists. Both have
the duty to recognize and mitigate overdose risk.
Most major wholesalers carry naloxone formulations
(Table 1). Outside of the inpatient setting, the most common
methods of naloxone administration are intranasal and intra-
muscular. Evzio is an intramuscular formulation of naloxone
in the form of an auto-injector (Beletsky, 2015).
To maintain its shelf life of 12 to 18 months, the product
should only be drawn (for the intramuscular injection)
or screwed (for the intranasal spray) into the syringe immedi-
ately before use. To maintain the shelf life, store at room
FIGURE 1. American Heart Association Opioid-Associated Life-Threatening Emergency (Adult) Algorithm. Reprinted with
permission. Circulation. 2015;132:S501-S518.  2015 American Heart Association, Inc. (http://circ.ahajournals.org/content/
132/18_suppl_2/S501.long).
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temperature, avoid environments with fluctuating extreme
temperatures like inside unattended automobiles, and away
from direct light (International Medications Systems Limited,
2015). Previously, the only option for intranasal naloxone was
with the use of the intramuscular formulation with a luer-lock
mucosal atomizer device (MAD), which must be stocked
separately and does not have a national drug code. However,
in November of 2015, the FDA approved a nasal naloxone
spray, which requires no assembly (U.S. Food and Drug
Administration, 2015). It is important to consider the patient’s
individual preferences and needs when choosing between
naloxone formulations.
A growing number of public and private insurers are
covering naloxone formulations. Pharmacists can determine
coverage and prior authorization requirements. The cost of
naloxone varies by formulation and distributor, but is around
$40 to $150 for an intranasal regimen—less for the intra-
muscular regimen, more for the auto-injector—which may
place them out of reach for many uninsured patients
(Massachusetts Department of Public Health, 2015). Kale´o,
the manufacturer of the auto-injector (Evzio), has a patient
assistance program that limits the out-of-pocket cost for
eligible patients (Evzio, 2015). The MAD has an out-
of-pocket cost of around $5 each.
Three models exist for accessing naloxone rescue kits
through a pharmacy (Green et al., 2015b). First, a prescriber
can write a prescription for naloxone and the patient can fill it
at the pharmacy. There, pharmacists can determine if nalox-
one is covered by the patient’s insurance. Pharmacy staff
should demonstrate the assembly and use of naloxone, and
also provide further information on how to prevent, recognize,
and respond to overdoses. Second, prescribers can write a
prescription and, if permitted by state law, dispense the
naloxone onsite. Third, pharmacies can provide naloxone
directly to the patient via a pharmacist prescriber, or under
a standing order, protocol, or collaborative practice agreement
(CPA), explained in more detail below. In states that do not
permit standing orders, protocols, or CPAs, pharmacists
can contact the prescriber to have him or her call in or
electronically send a prescription.
Variability exists across the country regarding avail-
ability and regulation of naloxone. Providers are encouraged
to identify pharmacies in their areas that stock naloxone, and
be aware of their state-specific laws surrounding naloxone
prescribing.
The patient visits the pharmacy to pick up her naloxone.
The patient asks for some help to determinewhich is best for
her. ‘‘I’d be happy to demonstrate,’’ the pharmacist replies.
The Legal Environment for Naloxone
Prescribing and Dispensing
The legal environment for naloxone prescribing is in
general no different than that for any other prescription
medication. Prescribers must ensure that prescriptions are
TABLE 1. Naloxone Formulations and Features
Injectable (and Nasal)
Generic Intranasal Branded Injectable Generic Auto-injector Branded
FDA approval X (for IV, IM, SC) X X X
Layperson experience X X X
Fragile; requires assembly X X
Can titrate dose X X
Strength 1mg/mL 4mg/0.1 mL 0.4mg/mL or 4mg/10mL 0.4mg/0.4mL
Cost per kit $$ $$ $ $$$
Rx and quantity #2, 2mL Luer-Jet Luer-
Lock needleless syringe
plus #2 mucosal
atomizer devices
(MAD-300)
#1 two-pack of two 4-mg/
0.1mL intranasal devices
#2 single-use 1-mL vials or
#1 10-mL multidose fliptop
vial PLUS #2 3mL syringe
with 23 to 25 gauge 1–
1.5 inch IM needles
#1 two-pack of two 0.4mg/
0.4mL prefilled auto-injector
devices
Sig. (for suspected
opioid overdose)
Spray 1mL (1/2 of
syringe) into each nostril.
Repeat after 2 to
3minutes if no or
minimal response
Spray 0.1mL into one
nostril. Repeat with second
device into other nostril after
2 to 3minutes if no or
minimal response
Inject 1mL in shoulder or
thigh. Repeat after 2 to
3minutes if no or minimal
response
Inject into outer thigh as
directed by English voice-
prompt system. Place black
side firmly on outer thigh
and depress and hold for
5 seconds. Repeat with
second device in 2 to
3minutes if no or minimal
response
Some portions developed with funding from NIDA R01 DA034634.
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issued in good faith, in the usual course of professional
practice, and for a legitimate medical purpose (Abood,
2010). The prescription of naloxone for a patient at risk
of overdose satisfies all 3 criteria (Burris et al., 2009).
Whereas intranasal use with a MAD is technically
considered an off-label use of the intramuscular formulation,
prescription of the medication for intranasal administration
does not change liability risk. Depending on the setting, 20%
to 80% of all prescriptions are written off-label, and the use of
naloxone intranasally is a well-established practice (O’Reilly
and Dalal, 2003; Kerr et al., 2009; Wittich et al., 2012).
A recent review of relevant law discovered no instances in
which a prescriber or dispenser was sued for prescribing or
providing naloxone for community use (Davis et al., 2015a).
As with any medication, both prescriber and pharmacist
should ensure that the patient understands the indications
of the medication, possible side effects, and how to administer
it in the event of an overdose.
As legislators have realized the need to increase
naloxone access to laypersons, the majority of states have
implemented laws and regulations to expand opportunities for
naloxone prescription and distribution. Additionally, a num-
ber of states have passed laws that limit civil and criminal
liability for prescribers, dispensers, and administrators, and
also ‘‘Good Samaritans’’ who call for help in an overdose
emergency, and the overdose victim (Davis et al., 2013; Davis
and Carr, 2015).
Third Party Prescribing
In recognition of the fact that the person who is at risk
of overdose is often not the person that the clinician encoun-
ters (ie, often a friend or family member expresses concern
to the prescriber about another person at risk), a number of
state legislatures have taken action to permit prescribers
to prescribe naloxone to people with whom they do not have
a prescriber–patient relationship. This is termed ‘‘third party
prescribing.’’ In a state that allows for third party prescribing,
the legal risk in doing so is no different than that if the
prescriber were prescribing directly to the person at risk.
Typically, the actual prescription will be written in the name
of the person who has directly contacted the prescriber. As
of September 2015, 37 states had passed laws permitting third
party prescribing of naloxone. The question of whose insur-
ance gets billed for third party prescriptions is an unresolved
issue and policies currently differ from place to place.
Enhanced pharmacy access
Some pharmacists practicing in federal agencies such
as the Indian Health Service and Veterans Administration have
prescribing authority, and several states have recently passed
laws that permit some pharmacists to prescribe naloxone (U.S.
Department of Health andHuman Services, 1996; Clause et al.,
2001; Davis and Carr, 2015). Where the pharmacist is the
prescriber, he or she is generally bound by the same require-
ments that apply to physicians and other prescribers.
A majority of states have passed laws that permit
prescribers and pharmacists to establish CPAs or standing
or protocol orders for naloxone. In these states, a pharmacist
can dispense naloxone to any individual who meets criteria
specified in the agreement or order. Rules and requirements
are state-specific, though all states require a written
agreement between prescriber and the pharmacy or pharma-
cist that sets out the terms. As of September 2015, 27 states
permit pharmacy standing orders and 12 also permit naloxone
to be distributed by laypersons acting under the authority
of a prescriber at locations such as community-based organ-
izations and drug treatment centers (Davis et al., 2015b;
Wheeler et al., 2015). In many states, standing orders are
also used to authorize nonmedical first responders such as
firefighters and police officers to possess and administer
naloxone (Davis et al., 2014b, 2015a).
Immunity for Prescribers and Dispensers
Fear of legal consequences may still discourage some
medical professionals from issuing naloxone prescriptions
(Beletsky et al., 2007). To address this concern, 32 states
have changed their laws to provide full or partial civil
immunity to medical professionals who prescribe naloxone
as permitted by law, whereas 30 provide such immunity
to dispensers and 36 to the person who administers the
medication in the event of an overdose. Most of these laws
require that the medical professional not act negligently or
recklessly in prescribing or dispensing. Because of these laws,
prescribing or dispensing naloxone entails less risk in most
states than prescribing or dispensing other medications.
Good Samaritan Laws
Many people who use illicit drugs or medications other
than prescribed may be wary of calling 911 in an overdose for
fear of criminal sanctions. Overdose Good Samaritan laws,
sometimes known as medical amnesty laws, are intended to
encourage bystanders to call for help by providing limited
criminal immunity to the person that makes the call, and also
to the victim. This immunity is typically limited to relatively
minor crimes, although in some states it extends to violations
of probation or parole. For prescribers and pharmacists, it is
important to let patients prescribed naloxone know of these
laws, and reinforce the importance of not only administering
naloxone, but also calling emergencymedical response (Tobin
et al., 2005; Lagu et al., 2006; Pollini et al., 2006).
State-specific naloxone laws can be found at the
Public Health Law Research Program’s Law Atlas (www.
lawatlas.org).
CONCLUSIONS
Prescribers and pharmacists should acknowledge and
embrace their role in helping patients to prevent and respond
to opioid overdoses. Clinical and legal environments have
become more conducive to providing overdose prevention
education and naloxone rescue kits. Engaging prescribers and
pharmacists is crucial to addressing the overdose epidemic.
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